Syed Bilgrami, MBBS
About
Titles
Biography
Dr. Bilgrami received his Medical Degree from Dow Medical College in 1984. After Residency Training in Internal Medicine in Karachi, at Wayne State University Hospital, and at the University of Connecticut Health Center, he completed his Fellowship Training in Medical Oncology and Hematology at the University of Connecticut Health Center. He also did a special Fellowship in Bone Marrow Transplantation at the Fred Hutchinson Cancer Center in Seattle, Washington. Dr. Bilgrami joined the Faculty of the University of Connecticut Health Center in 1994 as an Assistant Professor of Medicine. He became the Deputy Director of the University of Connecticut Health Center Bone Marrow Transplant Program and was appointed Associate Professor of Medicine in 2000. Dr. Bilgrami has published extensively in the field of Clinical Bone Marrow Transplantation and is regarded as an expert in Blood Cancers.
Appointments
Medical Oncology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology
- Subset Medical Oncology Faculty
- Yale Cancer Center
Education & Training
- Fellowship
- University of Connecticut School of Medicine (1993)
- Fellowship
- University of Connecticut School of Medicine (1992)
- Resident
- Wayne State University School of Medicine (1989)
- MBBS
- Dow Medical College (1984)
Research
Research at a Glance
Yale Co-Authors
Publications Timeline
Mary Ellen Dwyer
Publications
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, Brander D, Cortese M, Cripe L, Davis R, Eradat H, Fakhri B, Fletcher C, Gaballa S, Hamid M, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps T, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens D, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach J, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 175-204. PMID: 38626800, DOI: 10.6004/jnccn.2024.0018.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaPredictor of improved survivalUndetectable minimal residual diseaseImmunoglobulin heavy chain variable region mutational statusMinimal residual diseaseManagement of patientsSelection of treatmentRelapsed/refractory CLL/SLLLymphocytic lymphomaResidual diseaseCombination regimensTP53 mutationsMutation statusPerformance statusLymphocytic leukemiaNCCN GuidelinesPatient agePrognostic implicationsToxicity profileDisease stageComorbid conditionsPatientsCLL/SLLCytogenetic variability
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date02/01/2023Recruiting ParticipantsAn Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
HIC ID2000022049RoleSub InvestigatorPrimary Completion Date08/31/2026Recruiting ParticipantsNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting ParticipantsA Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
HIC ID2000021088RoleSub InvestigatorPrimary Completion Date11/23/2020Recruiting Participants
Links & Media
News
- June 04, 2020
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as CT Magazine Best Doctors
- June 03, 2019
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as CT Magazine 'Best Doctors'
- April 13, 2018
Connecticut Magazine recognizes Yale Cancer Center and Smilow Cancer Hospital physicians as 'Best Doctors'